テキサスにおける筋炎の臨床試験
テキサス内の拠点で、筋炎に関する7件の研究が参加者を募集しています。
テキサス内の都市
公式研究テキスト（英語）
RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
- University of Texas Southwestern Medical Center - Accepting Juvenile Patients, Dallas
- Houston Methodist Hospital - Accepting Adult Patients, Houston
- University of Texas MD Anderson Cancer Center - Accepting Adult Patients, Houston
被験者募集中第2/3相
6歳〜75歳 · 全性別 · 2026/09/17更新 · NCT06154252Ublituximab in Autoantibody Positive Immune Mediated Necrotizing Myopathy
- University of Texas - Houston, Houston
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/17更新 · NCT07103746A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]
- Integrative Rheumatology of South Texas, Edinburg
- Arthritis & Rheumatology Research Institute, PLLC, Frisco
- Integrative Rheumatology of South Texas, Harlingen
- 他3件
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/15更新 · NCT05895786Descartes-08 in Autoantibody Myositis
- National Neuromuscular Research Institute, Austin
被験者募集中第2相
18歳以上 · 全性別 · 2026/08/17更新 · NCT07391605A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)
- Nkarta Investigational Site, Dallas
- Nkarta Investigational Site, Houston
被験者募集中第1/2相
18歳〜75歳 · 全性別 · 2026/08/07更新 · NCT06733935AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
- Artiva Investigational Site Arlington, Arlington
- Artiva Investigational Site Bellaire, Bellaire
- Artiva Investigational Site Irving, Irving
- 他4件
被験者募集中第2相
18歳以上 · 全性別 · 2026/07/31更新 · NCT06991114Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Sporadic Inclusion Body Myositis
- Austin Neuromuscular Center, Austin
- Austin Neuromuscular Center, Austin
被験者募集中早期第1相
45歳〜75歳 · 全性別 · 2026/01/16更新 · NCT06479863ClinicalTrials.govより、2026/10/02時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。